H Lee Moffitt Cancer, 12901 Magnolia Drive, FOB3, Tampa, FL 33612, USA.
Expert Rev Clin Immunol. 2011 May;7(3):295-300. doi: 10.1586/eci.11.15.
Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved for the treatment of chronic lymphocytic leukemia refractory to alemtuzumab and fludarabine. Ofatumumab has also demonstrated activity in other low-grade non-Hodgkin's lymphomas. However, the optimal time to use ofatumumab and in what patient population is debatable. This article will review some of the key clinical studies that led to the drug's approval, current recommended usage of the drug and significant future directions.
奥法妥珠单抗是一种新型抗 CD20 单克隆抗体，最近被批准用于治疗对奥滨尤妥珠单抗和氟达拉滨耐药的慢性淋巴细胞白血病。奥法妥珠单抗在其他低级别非霍奇金淋巴瘤中也显示出活性。然而，最佳使用奥法妥珠单抗的时间和适用患者人群仍存在争议。本文将回顾一些导致该药物批准的关键临床研究、目前推荐的药物使用方法以及未来的重要方向。
